After reviewing the results of the Yervoy and Keytruda...

After reviewing the results of the Yervoy and Keytruda combination trials and finding the response rates in refractory melanoma trials impressive Edison have increased the success probability for Cavatak to 40% from 35%, raising their target to $1.70 in the process.

Not sure if you can access their full report via http://www.edisoninvestmentresearch.com/
They were looking to circulate their research in Australia in the biotech field more widely. Mostly they cover foreign stocks, including biotechs.